Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 2 1

Status

Completed 12Active not recruiting 4Not yet recruiting 3Unknown 2Terminated 2Recruiting 2

Sponsor Class

OTHER 4

Study Type

Interventional 4

Sponsor

Cancer Type

Other hematologic neoplasm 4Myeloid 1Lymphoid 1

Conditions

Multiple Myeloma 10Leukemia, Myeloid, Acute 4Lymphoma, Large B-Cell, Diffuse 3Recurrence 2Waldenstrom Macroglobulinemia 1Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasms, Plasma Cell 1Neoplasms 1Myeloproliferative Disorders 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma, B-Cell 1Lymphoma 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Biphenotypic, Acute 1Gliosarcoma 1Glioblastoma 1Endometrial Neoplasms 1Dendritic Cell Sarcoma, Interdigitating 1

Interventions

Azacitidine 38Cytarabine 37venetoclax 34fludarabine 28Cyclophosphamide 21Daunorubicin 18fludarabine phosphate 17Decitabine 16Specimen Handling 15Tacrolimus 14Busulfan 13Injections 12Biopsy 12Melphalan 11Granulocyte Colony-Stimulating Factor 11CPX-351 11Mycophenolic Acid 10Idarubicin 10Stem Cell Transplantation 9Whole-Body Irradiation 8Etoposide 8decitabine and cedazuridine drug combination 7Thiotepa 7Mitoxantrone 7enasidenib 6Peripheral Blood Stem Cell Transplantation 6Methotrexate 6ivosidenib 5gilteritinib 5Gemtuzumab 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Active not recruiting × Leukemia, Myeloid, Acute × selinexor × Clear all
NCT02091245 2026-05-29

Phase I Trial of the Selective Inhibitor of Nuclear Export, KPT-330, in Relapsed Childhood ALL and AML

Dana-Farber Cancer Institute

Phase 1 Active not recruiting
16 enrolled
LymphoidMyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT04898894 2026-04-28

Study of Selinexor and Venetoclax in Combination With Chemotherapy in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia

St. Jude Children's Research Hospital

Phase 1 Active not recruiting
37 enrolled
Other hematologic neoplasm

Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute

NCT07437170 2026-02-27

Selinexor Combined With Induction Chemotherapy for Children With NUP98-positive AML

The Children's Hospital of Zhejiang University School of Medicine

Phase 2 Active not recruiting
10 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT07094464 2025-07-30

Maintenance Therapy With Selinexor and Azacitidine in TP53 Mutant AML/MDS After Transplantation

Chinese PLA General Hospital

Phase 1 Active not recruiting
20 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡